WO2004011945A3 - Molekulare marker für das cholangioläre karzinom - Google Patents

Molekulare marker für das cholangioläre karzinom Download PDF

Info

Publication number
WO2004011945A3
WO2004011945A3 PCT/EP2003/008243 EP0308243W WO2004011945A3 WO 2004011945 A3 WO2004011945 A3 WO 2004011945A3 EP 0308243 W EP0308243 W EP 0308243W WO 2004011945 A3 WO2004011945 A3 WO 2004011945A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccc
cholangiolar
molecular markers
carcinoma
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008243
Other languages
English (en)
French (fr)
Other versions
WO2004011945A2 (de
Inventor
Sabine Debuschewitz
Juergen Jobst
Stephan Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2002/008305 external-priority patent/WO2003010336A2/de
Application filed by Individual filed Critical Individual
Priority to AU2003253329A priority Critical patent/AU2003253329A1/en
Priority to EP03771105A priority patent/EP1525477A2/de
Publication of WO2004011945A2 publication Critical patent/WO2004011945A2/de
Publication of WO2004011945A3 publication Critical patent/WO2004011945A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft molekulare Marker, die beim cholangiolären Karzinom (CCC) auftreten. Sie umfasst insbesondere Gensequenzen bzw. davon codierte Peptide, die beim CCC gegenüber nicht malignen bzw. normalen Leberzellen in der Expression herauf- oder herabreguliert sind, sowie die Verwendung dieser Sequenzen zur Diagnose oder/und Therapie von CCC sowie zum Screening zur Identifizierung neuer Wirkstoffe für CCC. Weiterhin betrifft die Erfindung ein CCC-spezifisches Cluster als einzigartiges diagnostisches Mittel für CCC. Weiterhin betrifft die Erfindung die Diskriminierung von CCC und HCC (Leberzellkarzinom).
PCT/EP2003/008243 2002-07-25 2003-07-25 Molekulare marker für das cholangioläre karzinom Ceased WO2004011945A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003253329A AU2003253329A1 (en) 2002-07-25 2003-07-25 Molecular markers for cholangiolar carcinoma
EP03771105A EP1525477A2 (de) 2002-07-25 2003-07-25 Molekulare marker für das cholangioläre karzinom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/008305 WO2003010336A2 (de) 2001-07-25 2002-07-25 Molekulare marker beim hepatozellulären karzinom
EPPCT/EP02/08305 2002-07-25

Publications (2)

Publication Number Publication Date
WO2004011945A2 WO2004011945A2 (de) 2004-02-05
WO2004011945A3 true WO2004011945A3 (de) 2004-06-03

Family

ID=30775772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008243 Ceased WO2004011945A2 (de) 2002-07-25 2003-07-25 Molekulare marker für das cholangioläre karzinom

Country Status (3)

Country Link
EP (1) EP1525477A2 (de)
AU (1) AU2003253329A1 (de)
WO (1) WO2004011945A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5028615B2 (ja) * 2006-05-24 2012-09-19 国立大学法人金沢大学 遺伝子発現プロファイルによるｃ型肝硬変及び肝癌の検出
WO2012076723A1 (de) * 2010-12-10 2012-06-14 Mosaiques Diagnostics And Therapeutics Ag Verfahren und marker zur diagnose einer gallengangsstriktur und eines cholangiozellulären karzinoms im gallensaft

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002022746A (ja) * 2000-07-12 2002-01-23 Kyokuho Yagita 癌の早期診断法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002022746A (ja) * 2000-07-12 2002-01-23 Kyokuho Yagita 癌の早期診断法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE LAS MULAS J MARTIN ET AL: "Immunohistochemical evaluation of canine primary liver carcinomas: Distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin.", RESEARCH IN VETERINARY SCIENCE, vol. 59, no. 2, 1995, pages 124 - 127, XP009018425, ISSN: 0034-5288 *
KAWAI HIROSHI F ET AL: "alpha-Fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis.", HEPATOLOGY, vol. 33, no. 3, March 2001 (2001-03-01), pages 676 - 691, XP009018388, ISSN: 0270-9139 *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05 3 May 2002 (2002-05-03) *
RONCALLI MASSIMO ET AL: "Expression of new phenotypic markers in cholangiocarcinoma and putative precursor lesions.", JOURNAL OF SURGICAL ONCOLOGY, no. SUPPL. 3, 1993, First International Conference on Hepatobiliary Tumours;Milan, Italy; August 30-September 2, 1992, pages 173 - 174, XP009018389, ISSN: 0022-4790 *

Also Published As

Publication number Publication date
AU2003253329A1 (en) 2004-02-16
EP1525477A2 (de) 2005-04-27
WO2004011945A2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2003010336A3 (de) Molekulare marker beim hepatozellulären karzinom
WO2004085621A3 (en) Gene expression in breast cancer
WO1999034004A3 (en) Metastatic breast and colon cancer regulated genes
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
WO2006056480A3 (en) Means and methods for detecting methylated dna
EP2363460A3 (de) Säureaktive fungale Protease
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005059160A3 (en) Identification and verification of methylation marker sequences
WO2000022130A3 (en) Metastatic breast and colon cancer regulated genes
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2000050588A3 (en) Genes associated with diseases of the colon
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
WO2004062487A3 (en) Methods of detecting gene expression in normal and cancerous cells
EP1667716B8 (de) Zytotoxizitätsmediation in zellen die auf eine oberflächenexpression von cd44 hinweisen
WO2003069307A3 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
WO1999067384A3 (en) Prostate cancer-associated genes
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
EP1367138A3 (de) Marker für Brustkrebsprognose
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2004011945A3 (de) Molekulare marker für das cholangioläre karzinom
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003771105

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003771105

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003771105

Country of ref document: EP